Mineralys Therapeutics, Inc.
corporate_fare Company Profile
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for MLYS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Mineralys Reports Q4/FY25 Results, Strong Cash Runway, but Lorundrostat Misses Primary Endpoint in OSA Trial
- FDA Accepts NDA for Lorundrostat for Hypertension; Sets PDUFA Date and Reports Mixed OSA Trial Results
- Mineralys Therapeutics Files NDA for Lorundrostat, Anticipates Q1 Phase 2 OSA Data
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$154.65M
Diluted EPS
-$2.29
Op. Cash Flow
-$142.42M
Free Cash Flow
-$142.43M
Operating Income
-$170.6M
Cash & Equivalents
$172.92M
Debt / Equity
0.00×
Shares Outstanding
81.54M sh
Source: 10-K · filed 2026-03-12 · accession 0001933414-26-000056
show_chartPrice Chart
Loading chart...
feed MLYS - Filings & News (Page 2)
MLYS
Mar 12, 2026, 4:08 PM EDT
Price at Filing:
$26.21
Real-time Price:
$13.70
Change:
-$12.51 (-48%)
Market Cap:
$1.21B
MLYS
Mar 09, 2026, 4:36 PM EDT
Price at Filing:
$26.20
Real-time Price:
$13.70
Change:
-$12.50 (-48%)
Market Cap:
$1.21B
MLYS
Jan 06, 2026, 8:06 AM EST
Price at Filing:
$35.69
Real-time Price:
$13.70
Change:
-$21.99 (-62%)
Market Cap:
$1.21B